Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes
- PMID: 21248249
- DOI: 10.4049/jimmunol.1002296
Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes
Abstract
The E3 ubiquitin ligase Cbl-b regulates T cell activation thresholds and has been associated with protecting against type 1 diabetes, but its in vivo role in the process of self-tolerance has not been examined at the level of potentially autoaggressive CD4(+) T cells. In this study, we visualize the consequences of Cbl-b deficiency on self-tolerance to lysozyme Ag expressed in transgenic mice under control of the insulin promoter (insHEL). By tracing the fate of pancreatic islet-reactive CD4(+) T cells in prediabetic 3A9-TCR × insHEL double-transgenic mice, we find that Cbl-b deficiency contrasts with AIRE or IL-2 deficiency, because it does not affect thymic negative selection of islet-reactive CD4(+) cells or the numbers of islet-specific CD4(+) or CD4(+)Foxp3(+) T cells in the periphery, although it decreased differentiation of inducible regulatory T cells from TGF-β-treated 3A9-TCR cells in vitro. When removed from regulatory T cells and placed in culture, Cblb-deficient islet-reactive CD4(+) cells reveal a capacity to proliferate to HEL Ag that is repressed in wild-type cells. This latent failure of T cell anergy is, nevertheless, controlled in vivo in prediabetic mice so that islet-reactive CD4(+) cells in the spleen and the pancreatic lymph node of Cblb-deficient mice show no evidence of increased activation or proliferation in situ. Cblb deficiency subsequently precipitated diabetes in most TCR:insHEL animals by 15 wk of age. These results reveal a role for peripheral T cell anergy in organ-specific self-tolerance and illuminate the interplay between Cblb-dependent anergy and other mechanisms for preventing organ-specific autoimmunity.
Similar articles
-
Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo.J Immunol. 2006 Feb 1;176(3):1316-20. doi: 10.4049/jimmunol.176.3.1316. J Immunol. 2006. PMID: 16424156
-
T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14709-14. doi: 10.1073/pnas.1009209107. Epub 2010 Jul 28. Proc Natl Acad Sci U S A. 2010. PMID: 20668237 Free PMC article.
-
Tracing the action of IL-2 in tolerance to islet-specific antigen.Immunol Cell Biol. 2007 Jun;85(4):338-42. doi: 10.1038/sj.icb.7100049. Epub 2007 Mar 20. Immunol Cell Biol. 2007. PMID: 17372610
-
Tolerance to islet autoantigens in type 1 diabetes.Annu Rev Immunol. 2001;19:131-61. doi: 10.1146/annurev.immunol.19.1.131. Annu Rev Immunol. 2001. PMID: 11244033 Review.
-
Autoimmune tolerance and type 1 (insulin-dependent) diabetes mellitus.Diabetologia. 1992 Dec;35 Suppl 2:S49-59. doi: 10.1007/BF00586279. Diabetologia. 1992. PMID: 1478378 Review.
Cited by
-
Ndfip1 mediates peripheral tolerance to self and exogenous antigen by inducing cell cycle exit in responding CD4+ T cells.Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2067-74. doi: 10.1073/pnas.1322739111. Epub 2014 Jan 13. Proc Natl Acad Sci U S A. 2014. PMID: 24520172 Free PMC article.
-
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.Cell Cycle. 2014;13(12):1875-84. doi: 10.4161/cc.29213. Epub 2014 May 14. Cell Cycle. 2014. PMID: 24875217 Free PMC article. Review.
-
Immunological Phenotyping of Mice with a Point Mutation in Cdk4.Biomedicines. 2023 Oct 20;11(10):2847. doi: 10.3390/biomedicines11102847. Biomedicines. 2023. PMID: 37893220 Free PMC article.
-
Pancreatic draining lymph nodes (PLNs) serve as a pathogenic hub contributing to the development of type 1 diabetes.Cell Biosci. 2023 Aug 28;13(1):156. doi: 10.1186/s13578-023-01110-7. Cell Biosci. 2023. PMID: 37641145 Free PMC article. Review.
-
Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy.Int J Mol Sci. 2021 Oct 6;22(19):10800. doi: 10.3390/ijms221910800. Int J Mol Sci. 2021. PMID: 34639141 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous